Protalix BioTherapeutics (PLX)
(Delayed Data from AMEX)
$1.16 USD
-0.05 (-4.13%)
Updated May 2, 2024 03:59 PM ET
After-Market: $1.16 0.00 (0.00%) 4:52 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PLX 1.16 -0.05(-4.13%)
Will PLX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PLX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PLX
Analysts Offer Insights on NA Companies: PLUXEE N.V. (PLX) and Brazilian Rare Earths Ltd. (ASX: AU:BRE)
Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
Protalix BioTherapeutics GAAP EPS of $0.09 misses by $0.01, revenue of $65.49M beats by $1.54M
Earnings Scheduled For March 14, 2024